In this Energy Code Deep Dive, Dr. Mike Belkowski and co-host Don Bailey unpack a striking 2025 paper by Liu and colleagues on gastrointestinal cancers (especially gastric and colorectal tumors) and why we may be looking in the wrong place for answers. Instead of focusing only on DNA mutations, this episode explores the mitochondria as the cell’s decision-makers; the organelles that help determine whether a cell grows, rests, or dies. The hosts break down the paper’s framework of mitochondrial quality control (MQC) into three core pillars: biogenesis (make), dynamics (shape), and mitophagy(break/recycle). They explain how tumors hijack these systems to fuel growth, metastasis, and drug resistance — and how therapies may work by disrupting the cancer cell’s energy code, not just damaging DNA. The conversation also covers PGC-1α, fission/fusion proteins, mitophagy under hypoxia, chemo resistance, and a fascinating (and very weird) malaria-related finding that reinforces the core concept. The big takeaway: cancer may be less about a broken blueprint and more about a corrupted energy system. (Educational content only, not medical advice.) - Article Discussed in Episode: The role of mitochondrial biogenesis, mitochondrial dynamics and mitophagy in gastrointestinal tumors - Key Quotes From Dr. Mike: “There is no one-size-fits-all energy code.” “Cancer isn’t just a genetic accident, it’s a fundamental corruption of how the cell handles energy.” “The shape of the mitochondria literally determines how well chemotherapy works.” “Cancer operates in a Goldilocks zone.” “Proton beam therapy… also works by hacking the energy code.” - Key points GI cancers remain a massive global burden The episode opens with sobering numbers: millions of new GI tumor cases and deaths annually. Focus is specifically on gastric and colorectal cancers. The paper shifts focus from DNA to mitochondria Modern oncology often centers on mutations. This review argues mitochondria are not just “batteries” — they are decision-makers controlling cell fate. Cancer is framed as a corruption of the “energy code” The hosts describe tumors as hijacking mitochondrial decision-making. Cancer rewrites the systems that regulate growth, dormancy, and apoptosis. Mitochondrial Quality Control (MQC) is the core framework The paper’s model has three pillars: Biogenesis (making mitochondria) Dynamics (shaping mitochondria via fission/fusion) Mitophagy (recycling damaged mitochondria) The hosts summarize this as: “make, shape, and break.” Pillar 1: Biogenesis fuels tumor growth Tumors need energy to expand, so they ramp up mitochondrial production. PGC-1α is presented as the key “foreman” regulating this process. Cancer operates in a biogenesis Goldilocks zone Some biogenesis is necessary for tumor growth. But too much PGC-1α can push cells into apoptosis (cell death), making it a fragile balance. Excess biogenesis can become toxic to cancer Overproduction of mitochondria can trigger death pathways (via BAX/Bak-type mitochondrial apoptosis signaling, as described in the transcript). This creates a therapeutic opportunity: push tumor energy systems beyond their tolerance. Tumors actively silence genes that would normalize metabolism The episode describes a gastric cancer example where a gene is silenced/methylated to preserve the tumor’s metabolic advantage (including the Warburg effect dynamics). Proton beam therapy may work partly by disrupting mitochondrial balance The hosts note a non-obvious mechanism: Beyond DNA damage, proton therapy may force excess mitochondrial biogenesis and push tumors into collapse. Pillar 2: Mitochondrial dynamics = shape-shifting for survival Mitochondria constantly undergo: Fission (splitting) Fusion (merging) This is described with a “lava lamp” analogy. Fission supports metastasis Fragmented mitochondria are easier to move within the cell. Cancer uses this to bring energy to the “leading edge” during invasion and spread. Fusion/fission proteins are strategic levers The episode highlights: DRP1 (fission) MFN1, MFN2, OPA1 (fusion) Aggressive tumors exploit these pathways to support mobility and growth. Chemo resistance is partly an energy-grid strategy In Adriamycin-resistant cells, tumors increase fission and reduce fusion. By breaking mitochondrial networks into “islands,” they quarantine damage and survive drug stress. Mitochondrial shape influences chemotherapy effectiveness The episode emphasizes that mitochondrial structure is not cosmetic — it changes treatment response. The “energy grid” layout can determine whether toxicity spreads or is contained. Pillar 3: Mitophagy = recycling damaged engines Mitophagy is a mitochondria-specific form of autophagy. In healthy cells, it’s protective quality control (e.g., PINK1/Parkin pathway). Tumors weaponize mitophagy under stress In nutrient-poor or hypoxic tumor cores, cancer ramps up mitophagy to recycle parts and survive. The recycling center becomes a survival grocery store. Hypoxia/mitophagy dysregulation increases ROS stress The episode discusses loss of mitophagy regulators (e.g., BNIP3 in gastric cancer contexts), which alters ROS and tumor behavior. The Plasmodium (malaria parasite) finding reinforces the concept A surprising section describes how Plasmodium infection can suppress colon tumor growth. Not as a treatment idea, but as proof that disrupting mitochondrial biogenesis/mitophagy can collapse tumor survival systems. Drug resistance examples show tumors actively re-code metabolism 5-FU resistance: tumors increase PGC-1α to power through treatment. Oxaliplatin resistance: tumors use exosome-mediated changes and oxidative phosphorylation support. Natural compounds may act as mitochondrial “signal jammers” The hosts discuss compounds highlighted in the paper: Resveratrol (supports healthier mitochondrial biogenesis) 8-gingerol / ginger compounds (push mitophagy/apoptosis pathways) Xanthohumol (from hops; anti-proliferative effects) Metformin (preserves normal structure and may inhibit tumor fission) Metformin is framed as anti-metastatic via dynamics By inhibiting fission, metformin may keep tumor mitochondria from fragmenting. “Heavy engines” are harder to mobilize for metastasis. The future is targeted energy-code therapy, not just poisoning cells The episode contrasts blunt-force cytotoxic therapy with precision mitochondrial disruption. The goal: break the tumor’s energy balancing system. There is no universal mitochondrial strategy across cancers The hosts stress a key warning: the mitochondrial “code” is personalized. What helps one tumor survive may kill another. Precision oncology will require mapping mitochondrial behavior Future treatment may need profiling of tumor energy patterns: fission-dominant vs fusion-dominant biogenesis-sensitive vs biogenesis-dependent mitophagy-dependent states Final philosophical takeaway: cancer may awaken an ancient survival program The episode closes with an evolutionary lens: Since mitochondria originated from ancient bacteria, tumors may be exploiting deeply conserved survival behaviors. - Episode timeline 0:00–1:02 — Opening: the GI cancer burden and the central premise The episode opens with global GI cancer incidence/death numbers and introduces the 2025 Liu paper’s challenge to DNA-only cancer thinking. 1:02–2:16 — Mitochondria as decision makers The hosts reframe mitochondria as active regulators of cell fate (growth, dormancy, death), not just batteries. 2:16–3:13 — Mitochondrial Quality Control (MQC): the 3 pillars They introduce the “factory” analogy and the three MQC pillars: Biogenesis Dynamics Mitophagy (“Make, shape, and break.”) 3:13–6:45 — Pillar 1: Biogenesis and the PGC-1α Goldilocks zone How tumors ramp up mitochondrial production PGC-1α as the “foreman” Too much biogenesis can trigger apoptosis Tumor methylation/silencing strategies Proton beam therapy as energy-code disruption 6:45–10:50 — Pillar 2: Dynamics (fission/fusion) and metastasis/drug resistance “Lava lamp” analogy for fission vs fusion DRP1, MFN1/2, OPA1 roles Why fragmented mitochondria help invasion Adriamycin resistance and mitochondrial “islanding” How mitochondrial shape affects chemo response 10:50–14:00 — Pillar 3: Mitophagy and tumor survival under stress Mitophagy as mitochondrial-specific autophagy PINK1/Parkin pathway basics Tumors using mitophagy to survive nutrient-poor cores Hypoxia, ROS, and regulator changes Plasmodium/malaria finding as proof-of-concept for breaking tumor energy systems 14:00–17:42 — Therapeutic implications: resistance + natural compounds + metformin 5-FU and oxaliplatin resistance as mitochondrial adaptation Resveratrol, ginger compounds, xanthohumol Metformin’s role in protecting normal mitochondria while inhibiting tumor fission Shift toward targeting machinery, not just poisoning cells 17:42–18:53 — Personalization warning: no universal energy code Different tumors respond differently to fission/fusion/biogenesis Precision oncology will require tumor-specific mitochondrial profiling 18:53–19:58 — Closing thought: the ancient mitochondrial survival program Endosymbiotic theory Is cancer reawakening an ancient bacterial survival strategy? Final takeaway: ask what’s happening in the mitochondria - Dr. Mike's #1 recommendations: Deuterium depleted water: Litewater (code: DRMIKE) EMF-mitigating products: Somavedic (code: BIOLIGHT) Blue light blocking glasses: Ra Optics (code: BIOLIGHT) Grounding products: Earthing.com - Stay up-to-date on social media: Dr. Mike Belkowski: Instagram LinkedIn BioLight: Website Instagram YouTube Facebook
